Biomea Fusion Stock (NASDAQ: BMEA) stock price, news, charts, stock research, profile.
Open | $11.410 |
Close | $11.160 |
Volume / Avg. | 1.671M / 1.013M |
Day Range | 10.950 - 11.870 |
52 Wk Range | 8.125 - 43.690 |
Market Cap | $400.525M |
P/E Ratio | - |
Dividend Yield | - |
Exchange | NASDAQ |
RSI | 33 |
Short Interest | 67.59% |
Days to Cover | 14.88 |
Name |
---|
Revenue Change |
Gross Change |
EBITDA Change |
EBIT Change |
Earnings Change |
You can purchase shares of Biomea Fusion (NASDAQ: BMEA) through any online brokerage.
Other companies in Biomea Fusion’s space includes: Humacyte (NASDAQ:HUMA), Voyager Therapeutics (NASDAQ:VYGR), Larimar Therapeutics (NASDAQ:LRMR), Replimune Group (NASDAQ:REPL) and PepGen (NASDAQ:PEPG).
The latest price target for Biomea Fusion (NASDAQ: BMEA) was reported by Oppenheimer on Wednesday, April 3, 2024. The analyst firm set a price target for 70.00 expecting BMEA to rise to within 12 months (a possible 527.24% upside). 24 analyst firms have reported ratings in the last year.
The stock price for Biomea Fusion (NASDAQ: BMEA) is $11.16 last updated April 18, 2024 at 4:00 PM EDT.
There are no upcoming dividends for Biomea Fusion.
Biomea Fusion’s Q1 earnings are confirmed for Tuesday, April 30, 2024.
There is no upcoming split for Biomea Fusion.
Biomea Fusion is in the Health Care sector and Biotechnology industry. They are listed on the NASDAQ.